Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty
Foresee Pharmaceuticals Co., Ltd. · Puberty; Precocious, Central
Phase 3
Completed
94
2026-07
Industry sponsor intelligence
Foresee Pharmaceuticals Co., Ltd.Clinical Pipeline.
Lead-sponsor view of Foresee Pharmaceuticals Co., Ltd.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 3
- Recruiting
- 0
- Active
- 0
- Completed
- 1
- Results posted
- 0
- Avg enrollment
- 31
Pipeline overview
Programs by phase and activity.
Velocity
Foresee Pharmaceuticals Co., Ltd. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
3phase labels
Early Phase 10
Phase 10
Phase 20
Phase 33
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Triptorelin → | 2 | 0 | 0 | 2 | 0 | 0 |
| Leuprolide → | 1 | 0 | 0 | 1 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Search sponsor records
All Foresee Pharmaceuticals Co., Ltd. studies.
This page groups studies where Foresee Pharmaceuticals Co., Ltd. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
3 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT05493709Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious PubertyJul 20, 2026NCT06795178Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate CancerApr 27, 2025NCT06795191Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate CancerApr 27, 2025